top of page

Severe Malaria Program  


Severe malaria kills over 300,000 children a year in Africa and ‘scientists have confirmed that malaria parasites in Africa have developed resistance to a key family of drugs used to protect against them.’  Nature, Sept 2021.

Novapep’s Professor Mosnier co-authored a review paper demonstrating why APC, which should be an effective therapy in severe malaria, does not work.  The malaria parasite produces a protein which blocks APC’s activity  


The malaria parasite blocks the action of APC, but it cannot block G10’s mechanisms of action.

Novapep is developing a systemic form of G10 and Professor Mosnier is leading the G10 in severe malaria development activity.

Total funding for malaria control and elimination reached an estimated US$3 billion in 2019. Contributions from governments of endemic countries amounted to US$900 million, representing 31% of total funding. The WHO African Region carries a disproportionately high share of the global malaria burden.  In 2019, the region was home to 94% of malaria cases and deaths.

bottom of page